AMVUTTRA
(vutrisiran)

AMVUTTRA is formulated for targeted delivery to the liver, the primary source of TTR production. AMVUTTRA deploys the body’s natural silencing complex to act upstream of tetramer formation.

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

• cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.

• polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.